Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond

(2015) Yin Wu et al.   Expert Review of Anticancer Therapy

Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

(2015) Sebastiano Buti et al.   Future Oncology

Epithelial to mesenchymal transition is associated with rapamycin resistance

(2015) Ashley M. Holder et al.   Oncotarget

Anticancer Activity of a Broccoli Derivative, Sulforaphane, in Barrett Adenocarcinoma: Potential Use in Chemoprevention and as Adjuvant in Chemotherapy

(2014) Aamer Qazi et al.   Translational Oncology

Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines

(2013) Reza Bayat Mokhtari et al.   BMC CANCER

Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial–mesenchymal transition and activation of Akt/GSK-3β/Snail signaling

(2013) Jiaxing Zhang et al.   CARCINOGENESIS

Acetazolamide triggers death inducing autophagy in T-47D breast cancer cells

(2013) Raziye Mohammadpour et al.   CELL BIOLOGY INTERNATIONAL

Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: Characterization, metabolism, and interconversion

(2012) Besma Abbaoui et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche

(2012) F E Lock et al.   ONCOGENE

Emerging therapies for urothelial cancer

(2011) César Serrano et al.   CANCER TREATMENT REVIEWS

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

(2011) E. Chiong et al.   CLINICAL CANCER RESEARCH

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

(2011) Didier Roulin et al.   Molecular Cancer

Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics

(2010) Vanessa Rausch et al.   CANCER RESEARCH

Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues

(2010) Y. Ding et al.   CARCINOGENESIS

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

(2010) Christina Barbara Ching et al.   LABORATORY INVESTIGATION

Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts

(2010) Sean Carlin et al.   PLoS One

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

(2009) David J. McConkey et al.   CANCER AND METASTASIS REVIEWS

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination Treatment with Resveratrol and Sulforaphane Induces Apoptosis in Human U251 Glioma Cells

(2009) Hao Jiang et al.   NEUROCHEMICAL RESEARCH

Novel therapeutics in metastatic bladder cancer

(2008) Alexandros Lekas et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: Role of dendritic cells

(2008) Hyon-Jeen Kim et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma

(2008) Xiao-Feng Wang et al.   PHYTOTHERAPY RESEARCH